BridgeBio to Host Autosomal Dominant Hypocalcemia Type 1 (ADH1) Investor Webinar on Wednesday, September 10th at 8:00 am ET
Rhea-AI Summary
BridgeBio Pharma (Nasdaq: BBIO) announced an upcoming investor webinar scheduled for September 10, 2025, at 8:00 am ET. The webinar will feature Dr. Rachel Gafni, Senior Research Physician at the National Institute of Dental and Craniofacial Research (NIH) and Principal Investigator for the CALIBRATE Phase 3 trial.
The presentation will focus on autosomal dominant hypocalcemia type 1 (ADH1), including disease pathophysiology, unmet medical needs, and the potential of encaleret as a treatment. Executive team members will discuss the ongoing Phase 3 CALIBRATE study, with topline results expected in fall 2025.
Positive
- None.
Negative
- None.
News Market Reaction 14 Alerts
On the day this news was published, BBIO gained 3.68%, reflecting a moderate positive market reaction. Our momentum scanner triggered 14 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $357M to the company's valuation, bringing the market cap to $10.06B at that time.
Data tracked by StockTitan Argus on the day of publication.
PALO ALTO, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced the Company will host an investor webinar on Wednesday, September 10, 2025 at 8:00 am ET with Rachel Gafni, M.D., Senior Research Physician at the National Institute of Dental and Craniofacial Research, part of the National Institutes of Health (NIH) and Principal Investigator and Steering Committee Co-Chair for CALIBRATE, the Company’s Phase 3 clinical trial for autosomal dominant hypocalcemia type 1 (ADH1).
Dr. Gafni will provide an overview of ADH1, specifically focusing on pathophysiology, the current unmet need, and the rationale for evaluating encaleret as a treatment for ADH1.
In addition to Dr. Gafni, executive members of the ADH1 program team will review the ongoing encaleret clinical development program and discuss the ongoing Phase 3 CALIBRATE study, for which topline results are expected in fall 2025.
To access the live webcast of BridgeBio’s investor webinar, please visit the “Events & Presentations” page within the Investors section of the BridgeBio website at http://investor.bridgebio.com. A replay of the webcast will be available on the BridgeBio website for 30 days following the event.
About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. (BridgeBio) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn, Twitter, Facebook, Instagram, and YouTube.
BridgeBio Media Contact:
Bubba Murarka, Executive Vice President
contact@bridgebio.com
(650)-789-8220
BridgeBio Investor Contact:
Chinmay Shukla, Senior Vice President, Strategic Finance
ir@bridgebio.com
FAQ
When is BridgeBio's ADH1 investor webinar and how can investors access it?
Who is presenting at BridgeBio's ADH1 investor webinar?
What is the focus of BridgeBio's upcoming investor webinar?
When are the topline results expected for BridgeBio's Phase 3 CALIBRATE study?
